Orbical-D3 (Colecalciferol, Calcium Carbonate)

Colecalciferol is converted in the liver to 25‑hydroxyvitamin D and then in the kidney to the active form 1,25‑dihydroxyvitamin D. This active hormone binds to vitamin D receptors in the intestine, stimulating the production of calcium‑binding proteins that increase dietary calcium absorption, which is essential for bone formation and maintenance.

The appropriate dose of Orbical-D3 is determined by the prescribing healthcare professional based on the patient’s age, clinical condition, baseline vitamin D and calcium levels, and other individual factors. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose on their own.

Orbical-D3 may be used during pregnancy or lactation only if the prescriber judges that the potential benefits outweigh any possible risks. Vitamin D and calcium are important for fetal bone development, but dosing should be individualized and monitored by a qualified healthcare provider.

To place an order, submit an enquiry on the Orbical-D3 product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Unlike single‑ingredient vitamin D products, Orbical-D3 combines colecalciferol with calcium carbonate, offering both the hormonal stimulus for calcium absorption and the mineral itself. This dual formulation can be advantageous for patients who need simultaneous correction of vitamin D deficiency and calcium supplementation, reducing the need for separate products.

Orbical-D3 should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Orbical-D3 is taken orally, usually with food to enhance calcium absorption. The tablets should be swallowed whole with a glass of water. Patients should follow the specific administration instructions given by their healthcare professional.

The most serious risks include severe hypercalcemia, which can lead to kidney stones, cardiac arrhythmias, or neurological symptoms, and hypervitaminosis D, which may cause calcium overload and tissue calcification. Prompt medical attention is required if symptoms such as persistent vomiting, confusion, or severe abdominal pain occur.

Orbical-D3 is contraindicated in individuals with known hypersensitivity to any of its components, those with existing hypercalcemia, or patients with conditions such as sarcoidosis or other granulomatous diseases where vitamin D metabolism is altered. Consultation with a healthcare provider is essential before starting the supplement.